Teva Pharma (TEVA) Eyeing Wave Life Sciences (WVE); Finisar (FNSR) Upbeat Earnings


Israel’s Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) disclosed in an SEC filing ( SC 13D ) a 9% stake (1,875,000 shares) in WAVE Life Sciences Ltd. (Nasdaq:WVE), which debuted on the U.S. stock market last month.

WVE stock finished the regular session at $14.28, up $0.12 (or +0.85%), and 45,844 of its shares exchanged hands on Thursday

WAVE Life Sciences, a preclinical biopharmaceutical company that designs, develops, and commercializes nucleic acid therapeutic candidates, has 20.93M Shares Outstanding, Market Capitalization (intraday) of $298.93M and WVE stock range from November 11, 2015 to date is between $11.52 and $17.21 per share



Shares of Finisar Corp. (Nasdaq:FNSR) soared more than 14% in the extended session Thursday after the company delivered stronger-than-expected quarterly financial results

For its second quarter fiscal 2016, Finisar posted $321.1 million, an 8.1% increase year-over-year, and non-GAAP net income of $26.86 million, or $0.25 per diluted share, compared to non-GAAP net income of $23.99 million, or $0.23 per diluted share in the same quarter the prior year, exceeding the Capital IQ Consensus Estimate of $0.23 earnings per share on revenues of $313.86 million for the period

FNSR stock closed at $11.64, down $0.11 (or -0.94%), with a total volume of 3,507,321 shares traded on Thursday’s market activity

Finisar, a global technology leader for subsystems and components for fiber optic communications, has 106.59M Shares Outstanding, Market Capitalization (intraday) of $1.24B and FNSR stock 52-week range is from $10.66 to $23.38 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at